Innate Pharma S.A. (IPHA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Innate Pharma S.A. (IPHA) trades at $1.87 with AI Score 42/100 (Grade C). Innate Pharma S. A. is a biotechnology firm specializing in therapeutic antibodies for oncology and inflammatory diseases. Market cap: $175.60M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for IPHA: IPHA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IPHA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IPHA: the 1 perspectives are evenly split.
How is this calculated? →Innate Pharma S.A. (IPHA) Healthcare & Pipeline Overview
Innate Pharma S.A. is a biotechnology company focused on the discovery and development of therapeutic antibodies for oncology and inflammatory diseases, leveraging a strong clinical pipeline and strategic partnerships to advance innovative treatments.
What Is the Investment Thesis for IPHA?
Innate Pharma S.A. presents a compelling investment thesis driven by its robust clinical pipeline and strategic partnerships. The company has several assets in advanced clinical stages, including Monalizumab, which is currently in Phase III trials for various solid tumors, representing a potential market opportunity in the oncology sector valued at over $100 billion. Additionally, Lacutamab is being evaluated for multiple indications, including cutaneous T-cell lymphoma, which has a growing market as treatment options remain limited. The company’s strong gross margin of 100% reflects its focus on high-value therapeutic development, although its current profit margin of -1764.5% indicates significant investment in R&D. With ongoing collaborations with industry leaders, Innate Pharma is well-positioned to leverage these relationships for accelerated development and commercialization of its therapies. However, investors may want to evaluate the inherent risks associated with clinical trials and regulatory approvals, which could impact timelines and market entry.
Based on FMP financials and quantitative analysis
IPHA Key Highlights
- Market Cap of $175.60M indicates a small-cap biotechnology firm with significant growth potential.
- Gross Margin of 100.0% reflects the company's focus on high-value therapeutic development.
- Profit Margin of -1764.5% highlights the current investment in R&D over profitability.
- Beta of 0.89 suggests lower volatility compared to the broader market, indicating relative stability.
- No dividend yield, typical for biotechnology firms focusing on reinvestment into R&D.
Who Are IPHA's Competitors?
IPHA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| RHHBY Roche Holding AG | $51.62 | -2.68% | $332.48B | 61 |
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IPHA's Key Strengths?
- Robust clinical pipeline with multiple assets in advanced stages of development.
- Strong gross margin reflecting high-value therapeutic focus.
- Strategic partnerships with major industry players enhance development capabilities.
- Expertise in immuno-oncology, a rapidly growing field.
What Are IPHA's Weaknesses?
- Negative profit margin indicating high R&D expenditures relative to revenue.
- Dependence on successful clinical trial outcomes for pipeline assets.
- Limited market presence compared to larger competitors.
- No current revenue streams from marketed products.
What Are the Key Risks for IPHA?
- Financial-distress signal — its Altman Z-Score of -13.77 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory delays impacting the timeline for clinical trial results and product approvals.
- High competition in the biotechnology sector could affect market share and pricing.
- Dependence on successful outcomes from clinical trials for pipeline assets.
- Market volatility may influence investor sentiment and funding opportunities.
What Are the Growth Opportunities for IPHA?
- Expansion of Monalizumab: Monalizumab is currently in Phase III trials for various advanced solid tumors, including colorectal and lung cancers. The global market for immune checkpoint inhibitors is projected to reach $55 billion by 2027, driven by increasing cancer prevalence and demand for effective therapies. Successful trial outcomes could provide significant revenue streams and enhance Innate Pharma's market presence.
- Lacutamab's Clinical Development: With Lacutamab in Phase II trials targeting cutaneous T-cell lymphoma and refractory Sézary syndrome, the drug addresses unmet needs in rare cancers. The global market for T-cell lymphoma treatments is expanding, with an estimated value of over $7 billion by 2025. Positive trial results could lead to accelerated approval and market entry.
- Avdoralimab's Potential in Inflammatory Diseases: Avdoralimab is in Phase II development for various inflammatory conditions, including COVID-19. The global market for anti-inflammatory drugs is projected to grow significantly, reaching approximately $150 billion by 2028. This positions Innate Pharma to capitalize on growing demand for innovative treatments in this area.
- Strategic Collaborations: Innate Pharma's partnerships with industry leaders like AstraZeneca and Novo Nordisk A/S enhance its research capabilities and market access. These collaborations not only provide financial support but also facilitate shared expertise, accelerating the development of its pipeline assets and expanding its therapeutic reach.
- Preclinical Pipeline Advancements: The company maintains a robust preclinical pipeline, including innovative antibody programs such as IPH43 and IPH65. As these candidates progress toward clinical trials, they could provide additional revenue streams and diversify Innate Pharma's portfolio, further solidifying its position in the biotechnology sector.
What Opportunities Does IPHA Have?
- Expansion into new therapeutic areas through ongoing clinical trials.
- Potential for accelerated approvals for pipeline assets addressing unmet needs.
- Increasing global demand for innovative cancer therapies.
- Growth in strategic collaborations to enhance resource availability.
What Threats Does IPHA Face?
- Intense competition from established biotechnology and pharmaceutical companies.
- Regulatory hurdles and delays in clinical trial approvals.
- Market volatility affecting investment and funding opportunities.
- Potential for adverse clinical trial results impacting stock performance.
What Are IPHA's Competitive Advantages?
- Strong pipeline of innovative therapeutic antibodies targeting high unmet needs.
- Established partnerships with leading pharmaceutical companies enhance credibility and resources.
- Expertise in immuno-oncology positions the company uniquely in a competitive landscape.
- Proprietary technologies for antibody development provide a competitive edge.
- Focus on rare and complex diseases reduces competition and increases market potential.
What Does IPHA Do?
Founded in 1999, Innate Pharma S.A. is a biotechnology firm based in Marseille, France, dedicated to the discovery, development, and commercialization of therapeutic antibodies. The company primarily focuses on oncology indications, targeting both domestic and international markets, while also addressing inflammatory diseases and viral infections. Innate Pharma's clinical-stage pipeline includes several promising assets: Lacutamab (IPH4102), an anti-KIR3DL2 antibody currently in Phase II trials for cutaneous T-cell lymphoma and refractory Sézary syndrome; Monalizumab, an immune checkpoint inhibitor in Phase III trials for advanced solid tumors; and Avdoralimab (IPH5401), a monoclonal antibody in Phase II development for various inflammatory conditions and COVID-19. Other notable candidates include IPH5201, IPH5301, and IPH6101, each targeting different immunological pathways and mechanisms. The company also boasts an active preclinical pipeline, which includes innovative antibody programs aimed at enhancing therapeutic efficacy. Innate Pharma has established strategic partnerships with major industry players such as AstraZeneca, Novo Nordisk A/S, and Sanofi, enhancing its research capabilities and market reach. This collaborative approach has positioned Innate Pharma as a significant player in the biotechnology sector, with a commitment to advancing novel therapies for unmet medical needs.
What Products and Services Does IPHA Offer?
- Discover and develop therapeutic antibodies for oncology and inflammatory diseases.
- Conduct clinical trials to evaluate the safety and efficacy of its drug candidates.
- Engage in strategic partnerships with major pharmaceutical companies for co-development.
- Maintain a diverse pipeline of both clinical-stage and preclinical assets.
- Focus on addressing unmet medical needs in oncology and immunology.
- Leverage proprietary technologies to enhance drug development processes.
How Does IPHA Make Money?
- Generate revenue through strategic collaborations and licensing agreements with pharmaceutical companies.
- Focus on developing high-value therapeutic antibodies that can command premium pricing.
- Invest in R&D to advance clinical-stage assets toward commercialization.
- Utilize milestone payments and royalties from partnered programs to supplement income.
- Seek FDA and EMA approvals to bring novel therapies to market.
What Industry Does IPHA Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, personalized medicine, and immunotherapy. The global biotechnology market is expected to reach approximately $2.4 trillion by 2028, with oncology being a significant contributor due to the increasing incidence of cancer and the demand for innovative treatments. Innate Pharma S.A. operates within this dynamic landscape, focusing on therapeutic antibodies, a segment that has seen substantial investment and innovation. The competitive landscape includes major players like Amgen, Genentech, and Bristol-Myers Squibb, but Innate Pharma differentiates itself through its specialized focus on immuno-oncology and strategic collaborations, positioning itself for growth in a rapidly evolving market.
Who Are IPHA's Key Customers?
- Pharmaceutical companies seeking innovative therapeutic solutions.
- Healthcare providers looking for advanced treatment options for patients.
- Patients with unmet medical needs in oncology and inflammatory diseases.
- Investors interested in biotechnology and healthcare sectors.
- Research institutions collaborating on clinical trials and drug development.
Company Profile
Innate Pharma S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Marseille, FR. The company is led by CEO Jonathan E. Dickinson. IPHA has traded publicly since 2019.
F-Score 2/9Financial Health
Innate Pharma S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.77 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -78.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -35.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.1%, the inverse of the P/E and a quick read on earnings relative to price.
IPHA Valuation & Market Position
With a $175.60M market cap, Innate Pharma S.A. sits in the micro-cap segment of the market. Relative to its peer group, IPHA's quantitative score of 42/100 is below the peer average of 77/100.
FY2026 estForward Outlook
Wall Street analysts project Innate Pharma S.A. revenue of about $30.9M for fiscal 2026, with EPS near $-0.25. The estimate reflects 4 contributing analysts.
IPHA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Innate Pharma's upcoming clinical trials, indicating belief in the company's potential breakthroughs.
- Community sentiment has shifted positively as recent news highlights promising data from their immunotherapy research, attracting investor interest.
- Increased media coverage around immuno-oncology therapies has bolstered the company's visibility, leading to heightened investor enthusiasm.
- Analysts have noted the potential for strategic partnerships, which could enhance Innate's market position and accelerate product development.
Bear Case
- Concerns over the competitive landscape in the biotech sector have emerged, with analysts pointing out the challenges of standing out in a crowded field.
- Recent social media discussions reflect skepticism about the company's ability to deliver on its clinical trial promises, leading to cautious sentiment.
- Market perception has been tempered by the volatility of biotech stocks, as investors remain wary of regulatory hurdles and funding issues.
- Insider selling has raised red flags among some investors, suggesting that key stakeholders may have reservations about the company's future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IPHA Latest News
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Jun 12, 2026
-
Outcome of Innate Pharma’s 2026 Annual General Meeting
Yahoo! Finance: IPHA News · May 22, 2026
-
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Yahoo! Finance: IPHA News · May 19, 2026
-
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
prnewswire.com · May 18, 2026
IPHA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IPHA.
Price Targets
Wall Street price target analysis for IPHA.
IPHA MoonshotScore
What does this score mean?
The MoonshotScore rates IPHA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Friday's After-Market Session
Outcome of Innate Pharma’s 2026 Annual General Meeting
Innate Pharma to participate in the Jefferies Global Healthcare Conference
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Latest Innate Pharma S.A. Analysis
Leadership: Jonathan E. Dickinson
CEO
Jonathan E. Dickinson has extensive experience in the biotechnology and pharmaceutical industries, having held various leadership roles throughout his career. He has a strong background in drug development and strategic management, with a focus on advancing innovative therapies. Prior to joining Innate Pharma, he worked at several prominent biotech firms, where he contributed to the successful launch of multiple therapeutic products. He holds a degree in biotechnology and has been instrumental in shaping the strategic direction of Innate Pharma since his appointment.
Track Record: Under Jonathan E. Dickinson's leadership, Innate Pharma has advanced several key assets through clinical trials, establishing strategic partnerships that have strengthened the company's market position. His focus on innovation and collaboration has been pivotal in driving the company's research initiatives and expanding its therapeutic pipeline.
Innate Pharma S.A. ADR Information Sponsored
An American Depositary Receipt (ADR) is a negotiable certificate representing shares in a foreign company's stock. Innate Pharma S.A. operates as a Level II ADR, allowing U.S. investors to trade shares in the company on U.S. exchanges while providing a mechanism for foreign companies to access American capital markets.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 2
- ADR Ratio: 1:1
IPHA Healthcare Stock FAQ
What does Innate Pharma S.A. do?
Innate Pharma S.A. is a biotechnology company focused on discovering, developing, and commercializing therapeutic antibodies primarily for oncology and inflammatory diseases. The company has a robust clinical pipeline with several assets in various stages of development, including immune checkpoint inhibitors and monoclonal antibodies targeting specific cancer types and inflammatory conditions.
What is Innate Pharma S.A.'s drug pipeline status?
Innate Pharma S.A. has a diverse drug pipeline featuring several clinical-stage assets. Key candidates include Monalizumab, currently in Phase III trials for advanced solid tumors, and Lacutamab, which is in Phase II trials for cutaneous T-cell lymphoma. The company also has multiple preclinical programs aimed at enhancing its therapeutic offerings, positioning it well for future growth.
What are the main risks for IPHA?
Innate Pharma S.A. faces several risks, including regulatory delays that could impact the timeline for clinical trial results and product approvals. Additionally, high competition in the biotechnology sector may affect market share and pricing strategies. The company's dependence on successful clinical trial outcomes for its pipeline assets presents another risk, as adverse results could significantly impact its stock performance.
What are the key factors to evaluate for IPHA?
Innate Pharma S.A. (IPHA) holds an AI score of 42/100 (low). Not financial advice.
How frequently does IPHA data refresh on this page?
IPHA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IPHA's recent stock price performance?
Innate Pharma S.A. (IPHA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust clinical pipeline with multiple assets in advanced stages of development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IPHA overvalued or undervalued right now?
Valuing Innate Pharma S.A. (IPHA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IPHA?
Before investing in Innate Pharma S.A. (IPHA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.